Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17

Vaccine

Volumn 26, Issue 36, 2008, Pages 4758-4765

  Fiorentini, Simona ^a   Marsico, Stefania ^b   Becker, Pablo D ^c   Iaria, Maria Luisa ^a   Bruno, Rosalinda ^b   Guzmán, Carlos A ^c   Caruso, Arnaldo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF CALABRIA   (Italy)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

HIV 1 matrix protein p17; Neutralizing antibodies; Synthetic peptide based vaccine

Indexed keywords

EPITOPE; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE AT20; PROTEIN P17;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; EPITOPES, B-LYMPHOCYTE; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEMOCYANIN; HIV ANTIBODIES; HIV ANTIGENS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; VACCINES, SUBUNIT;

EID: 48649086131     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.082     Document Type: Article

References (39)

1. Staprans S.I., Barry A.P., Silvestri G., Safrit J.T., Kozyr N., Sumpter B., et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA 101 35 (2004) 13026-13031
2. Vaccination and enrollment are discontinued in phase II trials of Merck's investigational HIV vaccine candidate. Press release from Merck and the HIV Vaccine Trials Network. Whitehouse Station NJ and Seattle, WA (2007)
3. Reiher W.E., Blalock J.E., and Brunck T.K. Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2. Proc Natl Acad Sci USA 83 23 (1986) 9188-9192
4. Hofmann B., Langhoff E., Lindhardt B.O., Odum N., Hyldig-Nielsen J.J., Ryder L.P., et al. Investigation of immunosuppressive properties of inactivated human immunodeficiency virus and possible neutralization of this effect by some patient sera. Cell Immunol 121 2 (1989) 336-348
5. Nehete P.N., Chitta S., Hossain M.M., Hill L., Bernacky B.J., Baze W., et al. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 20 5-6 (2001) 813-825
6. Wang C.Y., Shen M., Tam G., Fang X.D., Ye J., Shen F., et al. Synthetic AIDS vaccine by targeting HIV receptor. Vaccine 21 1-2 (2002) 89-97
7. Misumi S., Endo M., Mukai R., Tachibana K., Umeda M., Honda T., et al. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression. J Biol Chem 278 34 (2003) 32335-32343
8. Fiorentini S., Marini E., Bozzo L., Trainini L., Saadoune L., Avolio M., et al. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH. Biopolymers 76 4 (2004) 334-343
9. Naylor P.H., Naylor C.W., Badamchian M., Wada S., Goldstein A.L., Wang S.S., et al. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc Natl Acad Sci USA 84 9 (1987) 2951-2955
10. Papsidero L.D., Sheu M., and Ruscetti F.W. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol 63 1 (1989) 267-272
11. Buratti E., Tisminetzky S.G., D'Agaro P., and Baralle F.E. A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE. J Virol 71 3 (1997) 2457-2462
12. Chargelegue D., Stanley C.M., O'Toole C.M., Colvin B.T., and Steward M.W. The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression. Clin Exp Immunol 99 2 (1995) 175-181
13. Binley J.M., Klasse P.J., Cao Y., Jones I., Markowitz M., Ho D.D., et al. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 71 4 (1997) 2799-2809
14. Fiorentini S., Marini E., Caracciolo S., and Caruso A. Functions of the HIV-1 matrix protein p17. New Microbiol 29 1 (2006) 1-10
15. De Francesco M.A., Caruso A., Fallacara F., Canaris A.D., Dima F., Poiesi C., et al. HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. AIDS 12 3 (1998) 245-252
16. De Francesco M., Baronio M., Fiorentini S., Signorini C., Bonfanti C., Poiesi C., et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc Natl Acad Sci USA 99 15 (2002) 9972-9977
17. Vitale M., Caruso A., De Francesco M.A., Rodella L., Bozzo L., Garrafa E., et al. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. Br J Haematol 120 2 (2003) 337-343
18. Marini E., Tiberio L., Caracciolo S., Tosti G., Guzman C.A., Schiaffonati L., et al. HIV-1 matrix protein p17 binds to monocytes and selectively stimulates MCP-1 secretion: role of transcriptional factor AP-1. Cell Microbiol 10 3 (2008) 655-666
19. Fiorentini S., Riboldi E., Facchetti F., Avolio M., Fabbri M., Tosti G., et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci USA 105 10 (2008) 3867-3872
20. Popovic M., Tenner-Racz K., Pelser C., Stellbrink H.J., van Lunzen J., Lewis G., et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA 102 41 (2005) 14807-14812
21. Murray P.S., Li Z., Wang J., Tang C.L., Honig B., and Murray D. Retroviral matrix domains share electrostatic homology: models for membrane binding function throughout the viral life cycle. Structure 13 10 (2005) 1521-1531
22. Foucjier R.A., Meyer B.E., Simon J.H., Fischer U., and Malim M.H. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 16 15 (1997) 4531-4539
23. Casella C.R., Raffini L.J., and Panganibam A.T. Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. Virology 228 2 (1997) 294-306
24. Kiernan R.E., Ono A., Englund G., and Freed E.O. Role of matrix in an early post-entry step in the human immunodeficiency virus type 1 life cycle. J Virol 72 5 (1998) 4116-4126
25. Nguyen D.H., and Hildreth J.E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74 7 (2000) 3264-3272
26. Holm K., Weclewicz K., Hewson R., and Suomalainen M. Human immunodeficiency virus type 1 assembly and lipid rafts: Pr55 (gag) associates with membrane domains that are largely resistant to Brij98 but sensitive to Triton X-100. J Virol 77 8 (2003) 4805-4817
27. Ono A., and Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 98 24 (2001) 13925-13930
28. Brugger B., Glass B., Haberkant P., Leibrecht I., Wieland F.T., and Kräusslich H.G. The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci USA 103 8 (2006) 2641-2646
29. Ono A., Ablan S.D., Crowe S.M., and Mak J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol 22 3 (2001) 217-227
30. Shkriabai N., Datta S.A., Zhao Z., Hess S., Rein A., and Kvaratskhelia M. Interaction of HIV-1 Gag with assembly cofactors. Biochemistry 45 13 (2006) 4077-4083
31. Saad J.S., Miller J., Tai J., Kim A., Ghanam R.H., and Summers M.F. From the cover: structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc Natl Acad Sci USA 103 30 (2006) 11364-11369
32. Yuan X., Yu X., Lee T.H., and Essex M. Mutations in the N-terminal region of human immunodeficiency virus type 1 matrix protein block intracellular transport of the Gag precursor. J Virol 67 11 (1993) 6387-6394
33. Spearman P., Wang J.J., Vander Heyden N., and Ratner L. Identification of human immunodeficiency virus type 1 Gag protein domain essential to membrane binding and particle assembly. J Virol 68 5 (1994) 3232-3242
34. Andreassen H., Bohr H., Bohr J., Brunak S., Bugge T., Cotterill R.M., et al. Analysis of the secondary structure of the human immunodeficiency virus (HIV) proteins p17, gp120, and gp41 by computer modeling based on neural network methods. J Acquir Immune Defic Syndr 3 6 (1990) 615-622
35. Sela M., and Arnon R. Synthetic approaches to vaccines for infectious and autoimmune diseases. Vaccine 10 14 (1992) 991-999
36. Dyson H.J., and Wright P.E. Antigenic peptides. FASEB J 9 January (1) (1995) 37-42
37. Stanfield R.L., Fieser T.M., Lerner R.A., and Wilson I.A. Crystal structures of an antibody to a peptide and its complex with peptide antigen at 2.8 A. Science 248 4956 (1990) 712-719
38. Muller S., Plaué S., Samama J.P., Valette M., Briand J.P., and Van Regenmortel M.H. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza virus haemagglutinin. Vaccine 8 4 (1990) 308-314
39. Spangler B.D. Binding to native proteins by antipeptide monoclonal antibodies. J Immunol 146 5 (1991) 1591-1595